Premium
Radiation‐induced lymphoid tumors and radiation lethality are inhibited by combined treatment with small doses of zinc aspartate and wr 2721
Author(s) -
Floersheim G. L.,
Christ A.,
Koenig R.,
Racine C.,
Gudat F.
Publication year - 1992
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910520419
Subject(s) - lymphoma , dose , zinc , medicine , radiation therapy , carcinogen , pharmacology , irradiation , nuclear medicine , chemistry , biochemistry , organic chemistry , physics , nuclear physics
Combined small doses of zinc aspartame and WR 2721 provided additive protection against radiation lethality in mice. Survival obtained with a small dose of WR 2721 which was ineffective alone could be enhanced to 83% by combining the drug with zinc aspartate, which on its own also displayed no effect. The survival of 25% provided by a higher dose of WR 2721 was increased significantly by adding zinc aspartate. Additivity was also tested in a model of radiation carcinogene‐sis. For this purpose, lethality and occurrence of lymphoid tumors induced by fractionated total‐body irradiation were studied in C57BI/6 mice treated with zinc aspartate and WR 2721. In order to reveal additive effects, both agents were used at sub‐optimal dosages. In mice subjected to 5 daily exposures of 1.9 Gy, the combination of zinc aspartate and WR 2721 was effective and enhanced the survival to 83% as compared with 25% afforded by WR2721 alone ( p < 0.005). Similarly, histological assessment of organ involvement with lymphoma revealed that zinc aspartate and WR 2721 alone did not bring about a significant reduction of lymphoma incidence. On the other hand, the combined agents diminished organ involvement with lymphoma to 9.1 % as against 90% in the controls ( p < 0.0005) and 62.5% with WR 2721 alone ( p < 0.025). Thus, combined treatment with zinc aspartate and WR 2721 also inhibited radiation‐induced lymphoid tumors. © 1992 Wiley‐Liss, Inc.